Candidate Markers of Olaparib Response from Genomic Data Analyses of Human Cancer Cell Lines
The benefit of PARP inhibitor olaparib in relapsed and advanced high-grade serous ovarian carcinoma (HGSOC) is well established especially in <i>BRCA1/2</i> mutation carriers. Identification of additional biomarkers can help expand the population of patients most likely to benefit from o...
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2021-03-01
|
| Series: | Cancers |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2072-6694/13/6/1296 |